He published on policies regarding orphan medicines and advanced therapies in Europe and internationally, on the European Clinical Trial Directive, and on the impact of biotechnology on healthcare systems.
He authored guidelines concerning orphan medicines and advanced therapies in Europe and globally, on the European Clinical Trial Directive, and on the effects of biotechnology on healthcare systems.